Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARV-393 |
| Synonyms | |
| Therapy Description |
ARV-393 is a proteolysis targeting chimera (PROTAC) targeting BCL6, which induces degradation of BCL6 and potentially inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): ND05) |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARV-393 | ARV 393|ARV393 | BCL6 Inhibitor 6 | ARV-393 is a proteolysis targeting chimera (PROTAC) targeting BCL6, which induces degradation of BCL6 and potentially inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): ND05) |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06393738 | Phase I | ARV-393 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Recruiting | USA | ESP | DNK | CAN | 0 |